Clene Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Clene Inc. (CLNN)
CIK: 0001822791
Period of Report: 2020-12-30

Reporting Person: Mortenson Mark (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	138924.00	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Incentive Stock Option (right to buy)	$2.3754		Common Stock (263955.00)		Direct
Incentive Stock Option (right to buy)	$0.144		Common Stock (687604.00)		Direct

Footnotes

F1: Awarded under the Clene Nanomedicine, Inc. 2014 Stock Plan on August 26, 2019 and currently exercisable. The options expire 10 years from the date of the grant.

F2: Awarded the right to buy 6,210,000 shares of Clene Nanomedicine common stock under the Clene Nanomedicine, Inc. 2014 Stock Plan on July 31, 2014. The reporting party exercised his right to purchase 1,000,000 shares of Clene Nanomedicine common stock on November 23, 2016. Following Clene Nanomedicine, Inc.'s merger, the unexercised options converted into a right to buy common stock of Clene, Inc. The unexercised options now represent the right to buy 687,604 shares of Clene, Inc. common stock. The unexercised options are all currently exercisable and expire 10 years from the date of the grant.